Hurley Capital’s Anixa Biosciences ANIX Stock Holding History

Hurley Capital’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-314	Closed	-$898	–	465
2025 Q1	$898	Buy	+314	New	+$898	﹤0.01%	448

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Hurley Capital's ANIX Position: Q2 2025 in Review

Hurley Capital sold out of Anixa Biosciences (ANIX) in Q2 2025, closing a stake of 314 shares — an estimated $898 sold.

Hurley Capital first reported a position in ANIX in Q1 2025 and held it in 1 quarter. The position peaked at $898 in Q1 2025. 66 funds tracked by Wall St. Rank hold ANIX as of Q2 2025.

Hurley Capital reported no remaining Anixa Biosciences position as of Q2 2025 after selling out during the quarter.
Hurley Capital sold 314 Anixa Biosciences shares in Q2 2025, an estimated $898.
Hurley Capital first reported a position in Anixa Biosciences in Q1 2025 and held it in 1 quarter.
Hurley Capital's Anixa Biosciences position peaked at $898 in Q1 2025.
66 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2025.

Based on Hurley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.